Use of percentage change in clinical trials
|
|
17
|
1407
|
July 22, 2024
|
Evaluating seizures in open-label studies
|
|
8
|
455
|
July 21, 2024
|
Appropriate to do lasso, then standard glm using variables with non-zero coef. from lasso?
|
|
1
|
180
|
July 2, 2024
|
Estimands from zero-inflated regression model
|
|
9
|
470
|
June 20, 2024
|
ITT analysis under equally high non-adherence in both arms in RCT
|
|
4
|
330
|
June 9, 2024
|
Can we think of competing-event as another form of non-event in terms of utility?
|
|
0
|
319
|
April 21, 2024
|
Overall survival vs disease-free survival and other surrogate endpoints
|
|
5
|
6934
|
April 11, 2024
|
Individual response
|
|
236
|
36895
|
March 24, 2024
|
Is Lithium Equivalent to Lecanemab in Slowing cognitive decline in Alzheimer's Disease?
|
|
0
|
483
|
February 23, 2024
|
Review of Trial at the Center of the Firestorm Over Early Connection of Patients to Ventilators during the Pandemic
|
|
34
|
3346
|
February 16, 2024
|
Does subtracting/or not, the mean-rank in Wilcoxon-Mann-Whitney make any difference?
|
|
4
|
445
|
February 1, 2024
|
Ranked analysis of ANCOVA
|
|
7
|
1082
|
January 21, 2024
|
AUC of each subgroup is smaller than overall AUC
|
|
7
|
4325
|
November 13, 2023
|
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times
|
|
2
|
735
|
October 3, 2023
|
About the interpret category
|
|
1
|
3097
|
October 3, 2023
|
Comparing "all active dose" to placebo - do we treat "all active dose" as one group or separate groups?
|
|
2
|
731
|
September 4, 2023
|
Guidance of analysis of longitudinal patient reported outcomes w.r.t Joint models
|
|
4
|
943
|
August 29, 2023
|
Design of Experiments in Economics vs Medicine: a Decision Theory POV
|
|
6
|
1781
|
July 27, 2023
|
Inferences from summary data - without seeing the data for a Cox PH model, do chi square tests tell us anything?
|
|
5
|
333
|
July 24, 2023
|
Case-control study with and corresponding subgroup
|
|
2
|
702
|
July 20, 2023
|
Impact of Model Intercepts on Ordinal Logistic Regression Outcome
|
|
7
|
865
|
June 22, 2023
|
P values and small sample size
|
|
6
|
836
|
June 20, 2023
|
Minimum PPV/NPV values to reach positive net benefit and net benefit avoided
|
|
10
|
1369
|
June 12, 2023
|
Outlier detection
|
|
3
|
1259
|
May 11, 2023
|
HR really close to 1 but significant - how to interpret and report?
|
|
9
|
1441
|
April 25, 2023
|
FDA "Bad Habits"
|
|
7
|
2070
|
March 4, 2023
|
Advice regarding a Directed Acyclic Graph and further analysis Plan
|
|
7
|
1399
|
January 22, 2023
|
Table 2 Fallacy?: Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
|
|
23
|
2751
|
January 4, 2023
|
R package to present summary results from many different mixed effects models
|
|
3
|
1067
|
December 28, 2022
|
Interpretation of subject-specific effect in a cross-over study
|
|
5
|
3612
|
November 28, 2022
|